InspireMD (NYSE:NSPR) Now Covered by StockNews.com

StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a research note released on Thursday. The firm issued a sell rating on the stock.

Other analysts have also issued reports about the company. Lake Street Capital assumed coverage on InspireMD in a report on Wednesday. They set a “buy” rating and a $5.00 price objective for the company. Piper Sandler reiterated an “overweight” rating and set a $4.50 price target on shares of InspireMD in a report on Tuesday, September 17th.

InspireMD Price Performance

NSPR opened at $3.09 on Thursday. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.42. The business has a fifty day simple moving average of $2.66 and a 200-day simple moving average of $2.68.

InspireMD (NYSE:NSPR) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. The business had revenue of $1.81 million during the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. During the same quarter in the prior year, the firm earned ($0.15) EPS. As a group, equities analysts expect that InspireMD will post -0.79 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in InspireMD stock. Parkman Healthcare Partners LLC bought a new position in shares of InspireMD, Inc. (NYSE:NSPR) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned 0.42% of InspireMD at the end of the most recent quarter. 44.78% of the stock is owned by institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.